Microarray-Based CD38 Peptide Probe Screening for Multiple Myeloma Imaging.
Xuejie LiYuanzhuo WangQi YangLele SongLei KangZhiyuan HuZihua WangPublished in: Molecular pharmaceutics (2023)
Assessing CD38 expression in vivo has become a significant element in multiple myeloma (MM) therapy, as it can be used to detect lesions and forecast the effectiveness of treatment. Accurate diagnosis requires a multifunctional, high-throughput probe screening platform to develop molecular probes for tumor-targeted multimodal imaging and treatment. Here, we investigated a microarray chip-based strategy for high-throughput screening of peptide probes for CD38. We obtained two new target peptides, CA-1 and CA-2, from a 10 5 peptide library with a dissociation constant ( K D ) of 10 -7 M. The specificity and affinity of the target peptides were confirmed at the molecular and cellular levels. Peptide probes were labeled with indocyanine green (ICG) dye and 68 Ga-DOTA, which were injected into a CD38-positive Ramos tumor-bearing mouse via its tail vein, and small animal fluorescence and positron emission tomography (PET) imaging showed that the peptide probes could show specific enrichment in the tumor tissue. Our study shows that a microchip-based screening of peptide probes can be used as a promising imaging tool for MM diagnosis.
Keyphrases
- pet imaging
- fluorescence imaging
- living cells
- single molecule
- positron emission tomography
- high throughput
- small molecule
- high resolution
- pet ct
- multiple myeloma
- computed tomography
- fluorescent probe
- systematic review
- randomized controlled trial
- photodynamic therapy
- drug delivery
- stem cells
- nk cells
- nucleic acid
- cell therapy
- long non coding rna
- pain management
- mesenchymal stem cells
- energy transfer